Roche and Biogen Idec halt ocrelizumab RA development on infection data and deaths
This article was originally published in Scrip
Executive Summary
Development of Roche and Biogen Idec's humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) has been halted after patients in clinical trials suffered serious opportunistic infections, some of which were fatal. The drug is also in Phase II development for relapsing-remitting multiple sclerosis (RRMS) and, at present, this study is ongoing.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.